Share the article

Understand  –  Why should I care?

Resistant bacteria cause treatment failures

Resistant bacteria already cause many infections worldwide. There are usually still functioning antibiotics available, but some bacterial infections are increasingly difficult to treat, and death tolls are rising.

Antibiotic resistant bacteria, conservatively calculated, already cause more than 500,000 deaths every year (data in references used to extrapolate the worldwide burden of resistance).

Examples of the impact of antibiotic resistant bacteria:

  • Reports from around the world describe emergence of Gram-negative bacteria that are resistant to all or nearly all antibiotics; infections with these bacteria are often associated with increased hospital stays and mortality rates. Vulnerable populations such as preterm babies and young children are especially at risk.
  • Estimates suggest that resistant bacteria are responsible for the deaths of 214,000 newborns with blood stream infection each year.
  • In a study from Pakistan, 37 of 78 newborns with Acinetobacter infection died. 71% of the bacteria were resistant to all antibiotics except one.
  • Already we cannot safely treat multidrug-resistant strains of Salmonella typhi, the cause for typhoid fever, which is a major killer of children in low- and middle-income countries.
  • Gonorrhea is a sexually transmitted disease that can have severe consequences such as infertility. Resistance to last-line antibiotics has already developed, and some cases are close to untreatable. With 106 million new cases/year, the consequences of total resistance would be devastating.
  • Tuberculosis is a serious bacterial infection typically affecting the lungs. Around 1.5 million people died of the disease in 2014, and it ranks as a leading cause of death worldwide together with HIV. Multidrug-resistant tuberculosis is now on the rise: treatment options are less effective, more often associated with side effects, and can ultimately fail.

Modern medicine under threat

Many modern health care interventions such as cancer therapy, different types of surgeries and organ transplants depend on antibiotics to prevent and cure infections. Since bacteria and other microorganisms are everywhere around us as well as in and on the body, the risk of infection during surgery or when using treatments that affects our immune system is high. Without functioning antibiotics these procedures would be very risky. The entire modern health care system currently relies on antibiotics, and without these drugs, modern medicine as we know it today would not function.

  • Estimations suggest that 38-51% of bacteria causing infections at surgical sites and 26% of chemotherapy-related bacterial infections in the US are resistant to standard antibiotic prophylaxis. A 30% reduction in antibiotic efficacy would lead to 120,000 additional infections each year, and 6300 deaths.
  • Infections are common in organ transplant patients. A study of transplant patients infected with multidrug-resistant bacteria reported mortality rates of more than 70%.

Read about what you can do to contribute in the work to stop the spread of antibiotic resistance here What can I do?

Selected Resources

 

Resource Description
Antimicrobial resistance advocacy briefs Advocacy briefs from WHO Europe. Describe the links between antimicrobial resistance (AMR) and other areas, sectors and diseases (including COVID-19 and cancer). For example, briefs focusing on the impact of AMR on the sustainable development goals, child and adolescent health, migrant health and food safety are provided.
Successful cancer treatment relies on effective antibiotics Policy brief from ReAct explaining how and why antibiotic resistance affects cancer care and the treatment outcomes of cancer patients.
Effective antibiotics – essential for children’s survival Fact sheet from ReAct providing key examples on how antibiotic resistance affects children around the world.
Antibiotic Resistant Bacteria: 10 of the Worst Information portal providing an overview of 10 dangerous and often antibiotic resistant bacteria – the diseases they cause, characteristics and resistance levels.
Faces of Antimicrobial Resistance. Report. A collection of real-life stories of how antibiotic resistance has affected American people by the Infectious Diseases Society of America.
Antimicrobial resistance – The biggest threat to cancer treatment Information portal describing the consequences of antibiotic resistance for cancer patients, developed by the Norwegian Cancer Society.

More from "Why should I care?"

1.
Centers for Disease Control and Prevention - CDC. Antibiotic resistance threats in the United States, 2013. (2013).
1.
World Health Organization: Regional Office for Europe. Antimicrobial resistance advocacy briefs. https://www.euro.who.int/en/health-topics/disease-prevention/antimicrobial-resistance/publications/2019/antimicrobial-resistance-advocacy-briefs.
1.
Newman, L. et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS One 10, e0143304 (2015).
1.
ReAct - Action on antibiotic resistance. New fact sheet: Effective antibiotics - essential for childrens’ survival – 2020. ReAct https://www.reactgroup.org/news-and-views/news-and-opinions/year-2020/new-fact-sheet-effective-antibiotics-essential-for-childrens-survival/ (2020).
1.
ReAct - Action on antibiotic resistance. New ReAct Policy Brief: Successful cancer treatment relies on effective antibiotics – 2020. ReAct https://www.reactgroup.org/news-and-views/news-and-opinions/year-2020/new-react-policy-brief-successful-cancer-treatment-relies-on-effective-antibiotics/ (2020).
1.
Laxminarayan, R. et al. Access to effective antimicrobials: a worldwide challenge. Lancet 387, 168–175 (2016).
1.
Nesta. Antibiotic Resistant Bacteria: 10 of the Worst. nesta.org.uk https://www.nesta.org.uk/feature/antibiotic-resistant-bacteria-10-worst/ (2014).
1.
European Centre for Disease Prevention and Control - ECDC & European Medicines Agency - EMEA. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and development of new antibacterial agents. (EUR-OP, 2009).
1.
World Health Organization - WHO. Global tuberculosis report. WHO http://www.who.int/tb/publications/global_report/en/ (2017).
1.
The Norweigan cancer society. Antimicrobial resistance - The biggest threat to cancer treatment. The Norweigan cancer society https://kreftforeningen.no/antimicrobial-resistance/.
1.
Biderman, P., Bugaevsky, Y., Ben-Zvi, H., Bishara, J. & Goldberg, E. Multidrug-resistant Acinetobacter baumannii infections in lung transplant patients in the cardiothoracic intensive care unit. Clin Transplant 29, 756–762 (2015).
1.
Tsai, M.-H. et al. Risk Factors and Outcomes for Multidrug-Resistant Gram-Negative Bacteremia in the NICU. Pediatrics peds.2013-1248 (2014) http://doi.org/10.1542/peds.2013-1248.
1.
Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E. & Vardakas, K. Z. Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections. Emerg Infect Dis 20, 1170–1175 (2014).
1.
van Duin, D., Kaye, K. S., Neuner, E. A. & Bonomo, R. A. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn. Microbiol. Infect. Dis. 75, 115–120 (2013).
1.
Saleem, A. F., Ahmed, I., Mir, F., Ali, S. R. & Zaidi, A. K. Pan-resistant Acinetobacter infection in neonates in Karachi, Pakistan. J Infect Dev Ctries 4, 30–37 (2010).
1.
Chittawatanarat, K., Jaipakdee, W., Chotirosniramit, N., Chandacham, K. & Jirapongcharoenlap, T. Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit. Infect Drug Resist 7, 203–210 (2014).
1.
Cegielski, J. P. et al. Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance. Clin. Infect. Dis. 62, 418–430 (2016).
1.
Teillant, A., Gandra, S., Barter, D., Morgan, D. J. & Laxminarayan, R. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis 15, 1429–1437 (2015).
1.
Infectious Diseases Society of America - IDSA. IDSA : Patient Stories. http://www.idsociety.org/Patient_Stories/.
1.
Blomberg, B. et al. Antimicrobial resistance predicts death in Tanzanian children with bloodstream infections: a prospective cohort study. BMC Infect. Dis. 7, 43 (2007).
1.
Cooke, F. J. & Wain, J. The emergence of antibiotic resistance in typhoid fever. Travel Med Infect Dis 2, 67–74 (2004).
1.
Wain, J., Hendriksen, R. S., Mikoleit, M. L., Keddy, K. H. & Ochiai, R. L. Typhoid fever. Lancet 385, 1136–1145 (2015).
1.
World Health Organization - WHO, World Health Organization & Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. (World Health Organization, 2012).
1.
Phumart, P. et al. Health and Economic Impacts of Antimicrobial Resistant Infections in Thailand : A Preliminary Study. Journal of Health Systems Research 6, 352–60 (2012).